|
|
|
|
|
|
|
|
|
|
"The PRECEDENT study is a randomized phase 2 clinical trial comparing the company's drug EC145 in combination with pegylated liposomal doxorubicin (PLD/Doxil(R)) to PLD alone for women with platinum-resistant ovarian cancer."
Thursday, March 04, 2010
Endocyte Announces DSMB Supports Continuation of Phase 2 PRECEDENT Study - EC145 combo
"The PRECEDENT study is a randomized phase 2 clinical trial comparing the company's drug EC145 in combination with pegylated liposomal doxorubicin (PLD/Doxil(R)) to PLD alone for women with platinum-resistant ovarian cancer."
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.